Metagenomi shares dropped 31% on Friday afternoon in a disappointing debut on the Nasdaq Global Select Market, highlighting the potential perils faced by preclinical biotechs seeking to go public, according to Seeking Alpha.
Tag Archive for: Metagenomi
Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.
Moderna-backed Metagenomi is a precision genetics medicines company with what it describes as a comprehensive genome editing toolbox consisting of programmable nucleases, base editors, RNA-mediated integration systems and CRISPR-based techniques.
Ionis Pharmaceuticals inked a collaboration deal with Metagenomi with the goal of adding DNA editing to its RNA-targeted technologies focused on up to four genetic targets.
